Three-dimensional visual technique based on CT lymphography data combined with methylene blue in endoscopic sentinel lymph node biopsy for breast cancer

Baiye Wang, Caifeng Ou, Jin-Gang Yu, Jianping Ye, Yunfeng Luo, Yu Wang, Pusheng ZhangEuropean 2022 · DOI

TL;DR

This paper introduces a novel three-dimensional visualization technique (3DVT) combined with CT lymphography (CT-LG) and methylene blue for improved sentinel lymph node biopsy (SLNB) in breast cancer patients. This approach significantly enhances the identification rate and accuracy of SLNs, offering a promising alternative to traditional methods, especially in regions with restrictions on radioactive tracers.

What Problem Does This Paper Address?

Sentinel lymph node biopsy (SLNB) is a crucial procedure for staging breast cancer, as the sentinel lymph node (SLN) is the first site of potential metastasis. Accurate identification of SLNs is vital for determining the extent of the disease and guiding treatment decisions. Current standard methods often rely on a combination of blue dye and radioactive isotopes. However, the use of radioactive materials presents challenges, particularly in developing countries due to strict regulations and high costs. While blue dye alone is an option, it can lead to lower detection rates and is highly dependent on surgeon skill. The paper addresses the need for a more accessible, accurate, and reliable method for SLN identification that overcomes the limitations of existing techniques.

Methods

The core innovation presented is a three-dimensional visualization technique (3DVT) built upon computed tomography-lymphography (CT-LG) data. Here's a breakdown of their approach:

  • CT Lymphography (CT-LG): Patients received an intradermal injection of a lymphatic contrast agent (a mix of lidocaine and iopamidol) around the areola. This was followed by a 256-multislice CT scan to capture enhanced images of the lymphatic system.
  • Image Segmentation and 3D Reconstruction: The CT-LG data was processed using specialized software (Smart Vision Works V1.0) to create individualized 3D models of the breast and axilla. This included detailed visualization of lymph nodes, blood vessels, and surrounding musculature.
  • Sentinel Lymph Node Localization: The 3D models allowed for precise identification of SLNs by tracing the path of the contrast agent through lymphatic vessels. The location of the SLN was then marked on the patient's skin.
  • Visual Simulation Surgery: The 3D models were used for virtual surgical planning, allowing surgeons to simulate the procedure and anticipate potential challenges.
  • Endoscopic Sentinel Lymph Node Biopsy (ESLNB): During the actual surgery, methylene blue was injected intradermally. The procedure was then performed endoscopically, guided by the pre-operative 3DVT markings and the intra-operative blue staining. This involved minimally invasive incisions to access and remove the SLNs.

The key novelty lies in the integration of CT-LG for detailed anatomical visualization with the established methylene blue dye for intraoperative guidance, all within a 3D framework for enhanced planning and execution.

Datasets

The study utilized data from 389 breast cancer patients who underwent surgical treatment between September 2018 and June 2020 at Zhujiang Hospital. These patients were selected based on specific inclusion and exclusion criteria, primarily focusing on early-stage breast cancer without signs of advanced metastasis or prior axillary treatment. The paper does not introduce a new benchmark dataset but rather evaluates their technique on a cohort of real patients.

Key Insights and Ideas

  • 3D Visualization is Key: The ability to create detailed 3D models from CT-LG data was crucial. It provided surgeons with an unprecedented understanding of the patient's unique anatomy, including the precise spatial relationships between SLNs, major blood vessels, and muscles.
  • Synergy of CT-LG and Methylene Blue: Combining the detailed anatomical roadmap from CT-LG with the direct visual cue of methylene blue dye proved highly effective. This dual approach compensated for the limitations of each method individually.
  • Accessibility Advantage: This technique offers a viable alternative to radioactive tracers, making advanced SLN mapping more accessible in regions where radioactive materials are restricted or costly.
  • Surgeon Experience Matters (Initially): The paper notes that some early cases of false negatives were attributed to the surgeon's learning curve with the new technique. As experience grew, the performance improved, highlighting the importance of training and proficiency.
  • Minimally Invasive Benefits: The use of endoscopy for SLNB, guided by 3DVT, not only improved accuracy but also contributed to better cosmetic outcomes and potentially reduced complications like lymphedema.

Key Results

The study reported highly encouraging results:

  • High Identification Rate: An impressive 100% identification rate of SLNs was achieved across all 389 patients.
  • Excellent Accuracy: The overall accuracy of the method was 93.83%.
  • Strong Sensitivity: The sensitivity of the technique was 93.43%.
  • Low False-Negative Rate: A significant finding was the low false-negative rate of 6.57%, which is comparable to or better than many existing methods.
  • Reduced Complications: Only one patient experienced upper limb lymphedema during the 12-month follow-up, suggesting a favorable safety profile.

Limitations and Future Work

The authors acknowledge several limitations:

  • Single Institution Study: The data was collected from a single institution, which may limit the generalizability of the findings.
  • Short Follow-up Period: The 12-month follow-up period is relatively short for assessing long-term oncological outcomes.
  • Lack of Long-Term Efficacy Data: Further studies are needed to track the long-term efficacy of this technique.

The authors suggest that more high-quality, large-scale randomized controlled clinical trials are needed to further validate these findings and solidify the role of 3DVT based on CT-LG as a standard SLN mapping modality. They also highlight the potential for this technique to benefit a wider range of breast cancer patients.

Summary updated

Abstract

Our 3DVT based on CT-LG data combined with methylene blue in ESLNB ensures a high identification rate of SLNs with low false-negative rates. It, therefore, has the potential to serve as a new method for SLN biopsy in breast cancer cases.
BibTeX
@inproceedings{wang2022three,
  author = {Baiye Wang and Caifeng Ou and Jin-Gang Yu and Jianping Ye and Yunfeng Luo and Yu Wang and Pusheng Zhang},
  title = {{Three-dimensional visual technique based on CT lymphography data combined with methylene blue in endoscopic sentinel lymph node biopsy for breast cancer}},
  booktitle = {European},
  year = {2022},
  doi = {10.1186/s40001-022-00909-3},
}
Figure